Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 704Carcinoma, Non-Small-Cell Lung 470Prostatic Neoplasms 420Neoplasms 380Multiple Myeloma 264Colorectal Neoplasms 261Lung Neoplasms 247Neoplasm Metastasis 229Melanoma 215Ovarian Neoplasms 191Leukemia, Myeloid, Acute 189Pancreatic Neoplasms 182Squamous Cell Carcinoma of Head and Neck 163Recurrence 147Carcinoma, Renal Cell 145Lymphoma 142Glioblastoma 138Lymphoma, Non-Hodgkin 135Stomach Neoplasms 128Triple Negative Breast Neoplasms 127Brain Neoplasms 124Carcinoma, Hepatocellular 123Leukemia, Lymphocytic, Chronic, B-Cell 122Uterine Cervical Neoplasms 117Head and Neck Neoplasms 117Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Urinary Bladder Neoplasms 113Lymphoma, Large B-Cell, Diffuse 105Sarcoma 102Lymphoma, Follicular 100

Interventions

lenvatinib 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Advanced Gastric or Gastroesophageal Junction Adenocarcinoma × Clear all
NCT05585580 2026-05-26

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

Qilu Hospital of Shandong University

Phase 2 Active not recruiting
59 enrolled
Gastrointestinal

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡